Halofuginone prevents estrogen-deficient osteoporosis in mice

Journal of Cellular Biochemistry

Volumn 113, Issue 10, 2012, Pages 3086-3092

  Deselm, Carl J ^a   Zou, Wei ^a   Teitelbaum, Steven L ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

estrogen; halofuginone; osteoclast; Osteoporosis

Indexed keywords

HALOFUGINONE; INTERLEUKIN 17; OSTEOCLAST DIFFERENTIATION FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DEVELOPMENT; CONTROLLED STUDY; ESTROGEN DEFICIENCY; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOLYSIS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TH17 CELL;

ANIMALS; BODY WEIGHT; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; DRUG EVALUATION, PRECLINICAL; ESTROGENS; INTERLEUKIN-17; MICE; OSTEOCLASTS; OSTEOGENESIS; OSTEOPOROSIS; OVARIECTOMY; PIPERIDINES; QUINAZOLINONES; RANK LIGAND;

EID: 84865015484     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.24185     Document Type: Article

References (37)

1. Adamopoulos IE, Chao CC, Geissler R, Laface D, Blumenschein W, Iwakura Y, McClanahan T, Bowman EP,. 2010. Interleukin-17A upregulates receptor activator of NF-kappaB on osteoclast precursors. Arthritis Res Ther 12: R29.
2. Allen MR, Burr DB,. 2007a. Mineralization, microdamage, and matrix: How bisphosphonates influence material properties of bone. BoneKEy-Osteovision 4: 49-60.
3. Allen MR, Burr DB,. 2007b. Three years of alendronate treatment results in similar levels of vertebral microdamage as after one year of treatment. J Bone Miner Res 22: 1759-1765.
4. Bauer DC, Garnero P, Hochberg MC, Santora A, Delmas P, Ewing SK, Black DM,. 2006. Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: The fracture intervention trial. J Bone Miner Res 21: 292-299.
5. Cenci S, Weitzmann MN, Roggia C, Namba N, Novack D, Pacifici R,. 2000. Estrogen deficiency induces bone loss by enhancing T cell production of TNFα. J Clin Invest 106: 1229-1237.
6. Choi ET, Callow AD, Sehgal NL, Brown DM, Ryan US,. 1995. Halofuginone, a specific collagen type I inhibitor, reduces anastomotic intimal hyperplasia. Arch Surg 130: 257-261.
7. de Jong E, Suddason T, Lord GM,. 2010. Translational mini-review series on Th17 cells: Development of mouse and human T helper 17 cells. Clin Exp Immunol 159: 148-158.
8. DeSelm CJ, Takahata Y, Warren J, Chappel JC, Khan T, Li X, Liu C, Choi Y, Kim YF, Zou W, Teitelbaum SL,. 2012. IL-17 mediates estrogen-deficient osteoporosis in an Act1-dependent manner. J Cell Biochem E Pub Ahead of Print.
9. Ferretti S, Bonneau O, Dubois GR, Jones CE, Trifilieff A,. 2003. IL-17, produced by lymphocytes and neutrophils, is necessary for lipopolysaccharide- induced airway neutrophilia: IL-15 as a possible trigger. J Immunol 170: 2106-2112.
10. Fujita T, Matsui T, Nakao Y, Watanabe S,. 1984. T lymphocyte subsets in osteoporosis. Effect of 1-alpha hydroxyvitamin D3. Miner Electrolyte Metab 10: 375-378.
11. Galic S, Oakhill JS, Steinberg GR,. 2010. Adipose tissue as an endocrine organ. Mol Cell Endocrinol 316: 129-139.
12. Goswami J, Hernandez-Santos N, Zuniga LA, Gaffen SL,. 2009. A bone-protective role for IL-17 receptor signaling in ovariectomy-induced bone loss. Eur J Immunol 39: 2831-2839.
13. Granot I, Halevy O, Hurwitz S, Pines M,. 1993. Halofuginone: An inhibitor of collagen type I synthesis. Biochim Biophys Acta 1156: 107-112.
14. Happel KI, Zheng M, Young E, Quinton LJ, Lockhart E, Ramsay AJ, Shellito JE, Schurr JR, Bagby GJ, Nelson S, Kolls JK,. 2003. Cutting edge: Roles of toll-like receptor 4 and IL-23 in IL-17 expression in response to Klebsiella pneumoniae infection. J Immunol 170: 4432-4436.
15. Hueber AJ, Asquith DL, Miller AM, Reilly J, Kerr S, Leipe J, Melendez AJ, McInnes IB,. 2010. Mast cells express IL-17A in rheumatoid arthritis synovium. J Immunol 184: 3336-3340.
16. Ivanov S, Bozinovski S, Bossios A, Valadi H, Vlahos R, Malmhall C, Sjostrand M, Kolls JK, Anderson GP, Linden A,. 2007. Functional relevance of the IL-23-IL-17 axis in lungs in vivo. Am J Respir Cell Mol Biol 36: 442-451.
17. Kolls JK, Linden A,. 2004. Interleukin-17 family members and inflammation. Immunity 21: 467-476.
18. Kotake S, Nanke Y, Mogi M, Kawamoto M, Furuya T, Yago T, Kobashigawa T, Togari A, Kamatani N,. 2005. IFN-gamma-producing human T cells directly induce osteoclastogenesis from human monocytes via the expression of RANKL. Eur J Immunol 35: 3353-3363.
19. Lam J, Takeshita S, Barker JE, Kanagawa O, Ross FP, Teitelbaum SL,. 2000. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 106: 1481-1488.
20. Liu L, Yang P, He H, Lin X, Jiang L, Chi W, Zhao C, Zhou H,. 2008. Leptin increases in Vogt-Koyanagi-Harada (VKH) disease and promotes cell proliferation and inflammatory cytokine secretion. Br J Ophthalmol 92: 557-561.
21. Lockhart E, Green AM, Flynn JL,. 2006. IL-17 production is dominated by gammadelta T cells rather than CD4 T cells during Mycobacterium tuberculosis infection. J Immunol 177: 4662-4669.
22. Maek ANW, Buranapraditkun S, Klaewsongkram J, Ruxrungtham K,. 2007. Increased interleukin-17 production both in helper T cell subset Th17 and CD4-negative T cells in human immunodeficiency virus infection. Viral Immunol 20: 66-75.
23. McGaha TL, Phelps RG, Spiera H, Bona C,. 2002. Halofuginone, an inhibitor of type-I collagen synthesis and skin sclerosis, blocks transforming-growth- factor-beta-mediated Smad3 activation in fibroblasts. J Invest Dermatol 118: 461-470.
24. Michel ML, Keller AC, Paget C, Fujio M, Trottein F, Savage PB, Wong CH, Schneider E, Dy M, Leite-de-Moraes MC,. 2007. Identification of an IL-17-producing NK1.1(neg) iNKT cell population involved in airway neutrophilia. J Exp Med 204: 995-1001.
25. Pacifici R,. 2010. The immune system and bone. Arch Biochem Biophys 503: 41-53.
26. Roggia C, Gao Y, Cenci S, Weitzmann MN, Toraldo G, Isaia G, Pacifici R,. 2001. Up-regulation of TNF-producing T cells in the bone marrow: A key mechanism by which estrogen deficiency induces bone loss in vivo. Proc Natl Acad Sci USA 98: 13960-13965.
27. Rosen HN, Moses AC, Garber J, Iloputaife ID, Ross DS, Lee SL, Greenspan SL,. 2000. Serum CTX: A new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy. Calcif Tissue Int 66: 100-103.
28. Sato K, Suematsu A, Okamoto K, Yamaguchi A, Morishita Y, Kadono Y, Tanaka S, Kodama T, Akira S, Iwakura Y, Cua DJ, Takayanagi H,. 2006. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 203: 2673-2682.
29. Seeman E, Delmas PD,. 2006. Bone quality-The material and structural basis of bone strength and fragility. N Engl J Med 354: 2250-2261.
30. Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster D, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Koval K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O'Keefe R, Papapoulos S, Sen HT, van der Meulen MC, Weinstein RS, Whyte M,. 2010. Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 25: 2267-2294.
31. Shin HC, Benbernou N, Esnault S, Guenounou M,. 1999. Expression of IL-17 in human memory CD45RO+ T lymphocytes and its regulation by protein kinase A pathway. Cytokine 11: 257-266.
32. Shin JH, Shin DW, Noh M,. 2009. Interleukin-17A inhibits adipocyte differentiation in human mesenchymal stem cells and regulates pro-inflammatory responses in adipocytes. Biochem Pharmacol 77: 1835-1844.
33. Sumarac-Dumanovic M, Stevanovic D, Ljubic A, Jorga J, Simic M, Stamenkovic-Pejkovic D, Starcevic V, Trajkovic V, Micic D,. 2009. Increased activity of interleukin-23/interleukin-17 proinflammatory axis in obese women. Int J Obes (Lond) 33: 151-156.
34. Sundrud MS, Koralov SB, Feuerer M, Calado DP, Kozhaya AE, Rhule-Smith A, Lefebvre RE, Unutmaz D, Mazitschek R, Waldner H, Whitman M, Keller T, Rao A,. 2009. Halofuginone inhibits TH17 cell differentiation by activating the amino acid starvation response. Science 324: 1334-1338.
35. Takeshita S, Kaji K, Kudo A,. 2000. Identification and characterization of the new osteoclast progenitor with macrophage phenotypes being able to differentiate into mature osteoclasts. J Bone Miner Res 15: 1477-1488.
36. Wei S, Kitaura H, Zhou P, Ross FP, Teitelbaum SL,. 2005. IL-1 mediates TNF-induced osteoclastogenesis. J Clin Invest 115: 282-290.
37. Zhao H, Ito Y, Chappel J, Andrews NW, Teitelbaum SL, Ross FP,. 2008. Synaptotagmin VII regulates bone remodeling by modulating osteoclast and osteoblast secretion. Dev Cell 14: 914-925.